Loading
A phase 1/2 trial of AZD4045, Daratumumab, Aldesleukin in multiple myeloma, run by AstraZeneca, now recruiting.
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT07681596 by AstraZeneca, with 101 participants planned, started 2026-07-27 and due to reach its primary completion in 2031-03-06. Interventions recorded: AZD4045, Daratumumab, Aldesleukin. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, AstraZeneca, Multiple myeloma.
Shares Daratumumab, Relapsed or refractory multiple myeloma, AstraZeneca, Multiple myeloma.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Aldesleukin (high-dose IL-2), Daratumumab, Multiple myeloma.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/